Elizabeth L. Hougen's most recent trade in Ionis Pharmaceuticals Inc was a trade of 13,562 Common Stock done . Disclosure was reported to the exchange on Jan. 29, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 13,562 | 139,869 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Sale of securities on an exchange or to another person at price $ 83.24 per share. | 29 Jan 2026 | 6,988 | 132,881 (0%) | 0% | 83.2 | 581,702 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 34,360 | 120,995 | - | - | Performance Restricted Stock Units | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2026 | 28,729 | 55,940 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2026 | 28,729 | 139,229 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Sale of securities on an exchange or to another person at price $ 75.22 per share. | 15 Jan 2026 | 12,922 | 126,307 (0%) | 0% | 75.2 | 971,993 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 12,885 | 68,825 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 25,770 | 25,770 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.77 per share. | 30 Sep 2025 | 49,800 | 160,300 (0%) | 0% | 53.8 | 2,677,746 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Sale of securities on an exchange or to another person at price $ 65.26 per share. | 30 Sep 2025 | 49,800 | 110,500 (0%) | 0% | 65.3 | 3,249,734 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2025 | 49,800 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Artiva Biotherapeutics Inc | Elizabeth L. Hougen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2025 | 13,750 | 13,750 | - | - | Director Stock Option (Right to Buy) | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 4,138 | 112,023 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Sale of securities on an exchange or to another person at price $ 32.44 per share. | 30 Jan 2025 | 1,523 | 110,500 (0%) | 0% | 32.4 | 49,404 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 46,500 | 108,556 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 31,000 | 86,635 | - | - | Performance Restricted Stock Units | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 23,887 | 84,669 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 23,887 | 116,755 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Sale of securities on an exchange or to another person at price $ 32.81 per share. | 15 Jan 2025 | 8,870 | 107,885 (0%) | 0% | 32.8 | 290,989 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 31,000 | 31,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Sale of securities on an exchange or to another person at price $ 49.54 per share. | 02 Feb 2024 | 2,162 | 92,868 (0%) | 0% | 49.5 | 107,105 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 4,140 | 95,030 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | L. Elizabeth Hougen | EVP, Finance & CFO | Sale of securities on an exchange or to another person at price $ 49.54 per share. | 01 Feb 2024 | 2,125 | 92,905 (0%) | 0% | 49.5 | 105,272 | Common Stock |
| Ionis Pharma Inc | Elizabeth Hougen L. | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 22,487 | 99,573 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | L. Hougen Elizabeth | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 22,487 | 62,056 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | L. Hougen Elizabeth | EVP, Finance & CFO | Sale of securities on an exchange or to another person at price $ 50.42 per share. | 16 Jan 2024 | 8,683 | 90,890 (0%) | 0% | 50.4 | 437,771 | Common Stock |
| Ionis Pharma Inc | L. Hougen Elizabeth | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 32,400 | 84,543 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Elizabeth Hougen L. | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 27,000 | 55,635 | - | - | Performance Restricted Stock Units | |
| Ionis Pharma Inc | L. Hougen Elizabeth | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 43,200 | 43,200 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | L. Elizabeth Hougen | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Dec 2023 | 45,225 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | L. Hougen Elizabeth | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 28 Dec 2023 | 45,225 | 120,884 (0%) | 0% | 47.3 | 2,140,952 | Common Stock |
| Ionis Pharma Inc | L. Elizabeth Hougen | EVP, Finance & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.50 per share. | 28 Dec 2023 | 43,798 | 77,086 (0%) | 0% | 50.5 | 2,211,799 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Other type of transaction at price $ 30.52 per share. | 28 Feb 2023 | 163 | 75,659 (0%) | 0% | 30.5 | 4,974 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 4,140 | 77,575 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Sale of securities on an exchange or to another person at price $ 40.59 per share. | 03 Feb 2023 | 2,079 | 75,496 (0%) | 0% | 40.6 | 84,392 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 23,154 | 52,143 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 23,154 | 81,715 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Sale of securities on an exchange or to another person at price $ 39.70 per share. | 17 Jan 2023 | 8,280 | 73,435 (0%) | 0% | 39.7 | 328,721 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2023 | 19,460 | 75,297 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2023 | 16,216 | 28,635 | - | - | Performance Restricted Stock Units | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 25,946 | 25,946 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Other type of transaction at price $ 28.97 per share. | 31 Aug 2022 | 202 | 58,561 (0%) | 0% | 29.0 | 5,852 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Other type of transaction at price $ 28.37 per share. | 28 Feb 2022 | 384 | 58,359 (0%) | 0% | 28.4 | 10,895 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 22,050 | 55,837 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 22,050 | 65,803 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.12 per share. | 18 Jan 2022 | 7,828 | 57,975 (0%) | 0% | 30.1 | 235,779 | Common Stock |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 16,559 | 77,887 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 12,419 | 12,419 | - | - | Performance Restricted Stock Units | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 33,118 | 33,118 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Elizabeth L. Hougen | EVP, Finance & CFO | Other type of transaction at price $ 33.80 per share. | 31 Aug 2021 | 166 | 43,753 (0%) | 0% | 33.8 | 5,610 | Common Stock |